Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered diabetes coach: a digital path to better Self-Care?

NCT ID NCT07787403

Disease control Sponsor: The Hong Kong Polytechnic University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This pilot trial tests a personalized AI platform called PIPE-AI, enhanced by DiabetesGPT, to see if it can help adults with prediabetes or type 2 diabetes improve their self-management and knowledge. Participants are randomly assigned to either use the AI platform for three months or receive usual care, with both groups undergoing assessments at the start and end of the study. The platform provides tailored health advice and support, and the trial measures changes in diabetes self-management, knowledge, and clinical markers like HbA1c.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PIPE-AI, a personalized interactive AI platform enhanced by DiabetesGPT, providing tailored health advice and diabetes self-management support.
What this could lead to
If effective, this AI platform could offer a scalable, personalized tool to help people with prediabetes or diabetes better manage their condition in primary care settings.
What could go wrong
This is a small pilot study, so results may not be conclusive or generalizable. The intervention is behavioral and digital, so its impact may vary based on user engagement and adherence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Diagnosed with prediabetes or diabetes by their family doctors. * Able to understand Chinese. * Possess a mobile phone that can install the app developed for this project. Exclusion Criteria: * Under legal guardianship. * Comorbid schizophrenia. * Intellectual disability. * Incompetent in giving consent. * Other significant cognitive disorders.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus, type 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Patient Participation prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus, type 2 Prediabetes Prediabetes / type 2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.